Balancing The Scales: The Ups And Downs Of Bioprocess Scale-Up

Dry Powder Inhalable Vaccines For Shelf Stability And Global Access

Navigating Your Holistic Approach To CCI For Biologic Drug Products

Accelerating Drug Development For Biologics: Flexible And Fast DNA-To-IND Programs

Capacity Update May 2024: Small Molecule APl And HPAPI Development

Leveraging Platforms To Create Vaccines At Pandemic Speed

Accelerate Your Bispecific Antibody Development

How Does bYlok Technology Work? How Can It Improve Bispecific Production?

Solving Bispecific Antibody Heavy-Light Chain Mispairing

Best Tech Transfer Practices To Optimize Clinical And Commercial Supply

Developing A mAb For A Small Biotech Developing Precision Medicines

Solving Bispecific Antibody Heavy-Light Chain Mispairing

Addressing Key Challenges Of High Concentration Formulation Development

Tailored CMC Solutions That Meet Needs Of Novel Molecular Biologic Formats

Inclusion Bodies: Mother Nature's Help Or Hindrance?

Improved Design And Production Of Bispecific Therapeutics

Precision Execution Of Bispecifics At Scale From Design To Delivery

In Silico, In Vitro Tools For Regulatory Submission, Feedback

Harnessing New Tech To Create Next-Generation GS-CHO Expression Solutions

Drug Product Process Characterization For Liquid And Lyophilized DP

Overcome Manufacturability, Expression, Early Material Generation Challenges

Predictive Modeling Of Concentration-Dependent Viscosity Behavior

Process Intensification To Improve Efficiency, Productivity

Reaching BLA Success: Fast-Track Approach To Process Characterization

CMC Strategy To Take Bispecifics From DNA To IND In 13 Months

How To Bring (Any) mRNA To Life: Simplifying Nucleic Acid Encapsulation

Accelerate Your Bispecific Antibody Development

Mitigate Risk Of Failure In Biotherapeutic Development

Hybrid Approach For Optimizing Transient Protein Expression In CHO Cells

Scalable Protein Expression With Pichia Pastoris

Particle Investigation: Going One Step Further Than Just The Identification

Identifying And Mitigating Potential For Immunogenicity, Immunotoxicity

An Alternative To Achieve Speed And Scalability To Microbial Expression For Next-Gen Therapeutics

Key Enablers For Late Phase Biologic Drug Development, Launch

Deciphering mRNA Immunogenicity: Early Assessment Of Human Immune Response

Effective Technology Transfer For Mammalian Derived Biopharmaceuticals

Expressing Next-Gen Immunotherapies And Other Advanced Biologics

Overcoming The Challenges In Fabs And Fc-Fusion Development Programs

Analytical Strategies To Address Common Development Challenges

Embrace Molecule Complexity With Optimized Expression Technologies

Pionyr: Selecting A CDMO To Scale-Up Manufacturing

Early Developability And Analytical Toolbox For The Production Of Multi-Chain Biotherapeutics

Balancing The Scales: The Ups And Downs Of Bioprocess Scale-Up

Accelerating Drug Development For Biologics: Flexible And Fast DNA-To-IND Programs

Challenges Of Moving A Bioconjugate Candidate From Clinic To Market

DNA To IND In 11 Months: Integrated Drug Substance, Drug Product Offering

Development, Manufacture Of Biopharmaceuticals In Microbial Systems

Trends, Challenges, And Opportunities In Bispecific Antibodies

Optimizing The Path To First-In-Human Clinical Trials: Design And De-Risk

Navigating Your Holistic Approach To CCI For Biologic Drug Products

Achieving Biologics License Application Success Using A Structured Approach

How Does bYlok Technology Work? How Can It Improve Bispecific Production?

Filling The Need For Integrated Bioconjugate Solutions

Leveraging Platforms To Create Vaccines At Pandemic Speed

Early Development To Clinic – De-Risking A Bioconjugate's Journey

Challenges Associated With In-Use Simulated Administration Of Biologics

Our Biotech Success — Surrozen

Our Biotech Success — Levicept

Our Biotech Success — Levicept

Achieving Biologics License Application Success Using A Structured Approach

Developing A mAb For A Small Biotech Developing Precision Medicines

Mitigate Risk Of Failure In Biotherapeutic Development

In Silico, In Vitro Tools For Regulatory Submission, Feedback

Tailored CMC Solutions That Meet Needs Of Novel Molecular Biologic Formats

DNA To IND In 11 Months: Integrated Drug Substance, Drug Product Offering

Overcoming The Challenges In Fabs And Fc-Fusion Development Programs

CMC Strategy To Take Bispecifics From DNA To IND In 13 Months

Early Developability And Analytical Toolbox For The Production Of Multi-Chain Biotherapeutics

Our Biotech Success — Surrozen

Embrace Molecule Complexity With Optimized Expression Technologies

Pionyr: Selecting A CDMO To Scale-Up Manufacturing

Overcome Manufacturability, Expression, Early Material Generation Challenges

Deciphering mRNA Immunogenicity: Early Assessment Of Human Immune Response

Overcome Manufacturability, Expression, Early Material Generation Challenges

Particle Investigation: Going One Step Further Than Just The Identification

Effective Technology Transfer For Mammalian Derived Biopharmaceuticals

Accelerating Drug Development For Biologics: Flexible And Fast DNA-To-IND Programs

Identifying And Mitigating Potential For Immunogenicity, Immunotoxicity

Process Intensification To Improve Efficiency, Productivity

Accelerate Your Bispecific Antibody Development

Trends, Challenges, And Opportunities In Bispecific Antibodies

Precision Execution Of Bispecifics At Scale From Design To Delivery

Scalable Protein Expression With Pichia Pastoris

An Alternative To Achieve Speed And Scalability To Microbial Expression For Next-Gen Therapeutics

Expressing Next-Gen Immunotherapies And Other Advanced Biologics

Solving Bispecific Antibody Heavy-Light Chain Mispairing

Hybrid Approach For Optimizing Transient Protein Expression In CHO Cells

Harnessing New Tech To Create Next-Generation GS-CHO Expression Solutions

Improved Design And Production Of Bispecific Therapeutics

How Does bYlok Technology Work? How Can It Improve Bispecific Production?

Leveraging Platforms To Create Vaccines At Pandemic Speed

Accelerating Drug Development For Biologics: Flexible And Fast DNA-To-IND Programs

Addressing Key Challenges Of High Concentration Formulation Development

Navigating Your Holistic Approach To CCI For Biologic Drug Products

Particle Investigation: Going One Step Further Than Just The Identification

Key Enablers For Late Phase Biologic Drug Development, Launch

Challenges Associated With In-Use Simulated Administration Of Biologics

Challenges Associated With In-Use Simulated Administration Of Biologics

Predictive Modeling Of Concentration-Dependent Viscosity Behavior

Inclusion Bodies: Mother Nature's Help Or Hindrance?

Development, Manufacture Of Biopharmaceuticals In Microbial Systems

Reaching BLA Success: Fast-Track Approach To Process Characterization

Balancing The Scales: The Ups And Downs Of Bioprocess Scale-Up

Rapid, Material-Sparing Feasibility Screening For Hot Melt Extrusion

Increase Spray Drying Throughput For Brick Dust Compounds

From Powder To Particles With Jet Milling

How To Deal With The Complexity Of Drugs In Clinical Development

Process Re-Design For Sustainability In Small Molecule Manufacturing

PBPK Modeling: Mitigating Absorption Risks In Early Drug Development

Local Delivery For Treatment Of Lung Cancer

Identify And Mitigate Absorption Risks With PBPK Modeling

Dry Powder Inhalable Vaccines For Shelf Stability And Global Access

How To Design An HPAPI Plant And Its Containment Systems

Particle Size Control Through Micronization: Challenges And Solutions

Pharmaceutical Spray Drying: Sustainable Commercial Best Practices

Solid Form Screening Of Active Pharmaceutical Ingredients

Environmental Sustainability: Use Case - Solvent Recovery

Chromatography, Purification & Isolation Technologies

Environmental Sustainability: Wastewater Incineration Reduction

Rapid Development Of Amorphous Solid Dispersions For Bioavailability

Meeting The Challenge Of Rising API Complexity

Streamlined Selection Of In Vivo Predictive Dissolution Media

Simultaneous Spray Drying: Dry Powder Inhaler Combination Formulations

Continuous Flow Techniques For Fine Chemical Manufacturing

How To Safely Handle Your Antibody Drug Conjugate

Dramatic Reduction Of Solvent Usage In Pharmaceutical Spray Drying

Capacity Update May 2024: Small Molecule APl And HPAPI Development

Pharmaceutical Spray Drying: Sustainable Commercial Best Practices

Identify And Mitigate Absorption Risks With PBPK Modeling

Rapid Development Of Amorphous Solid Dispersions For Bioavailability

Increase Spray Drying Throughput For Brick Dust Compounds

Particle Size Control Through Micronization: Challenges And Solutions

Dramatic Reduction Of Solvent Usage In Pharmaceutical Spray Drying

PBPK Modeling: Mitigating Absorption Risks In Early Drug Development

Streamlined Selection Of In Vivo Predictive Dissolution Media

Pharmaceutical Spray Drying: Sustainable Commercial Best Practices

Rapid Development Of Amorphous Solid Dispersions For Bioavailability

PBPK Modeling: Mitigating Absorption Risks In Early Drug Development

Simultaneous Spray Drying: Dry Powder Inhaler Combination Formulations

Identify And Mitigate Absorption Risks With PBPK Modeling

Dramatic Reduction Of Solvent Usage In Pharmaceutical Spray Drying

Streamlined Selection Of In Vivo Predictive Dissolution Media

Rapid Development Of Amorphous Solid Dispersions For Bioavailability

Local Delivery For Treatment Of Lung Cancer

Dramatic Reduction Of Solvent Usage In Pharmaceutical Spray Drying

From Powder To Particles With Jet Milling

Particle Size Control Through Micronization: Challenges And Solutions

Rapid, Material-Sparing Feasibility Screening For Hot Melt Extrusion

Increase Spray Drying Throughput For Brick Dust Compounds

PBPK Modeling: Mitigating Absorption Risks In Early Drug Development

Pharmaceutical Spray Drying: Sustainable Commercial Best Practices

Identify And Mitigate Absorption Risks With PBPK Modeling

Simultaneous Spray Drying: Dry Powder Inhaler Combination Formulations

Local Delivery For Treatment Of Lung Cancer

Dry Powder Inhalable Vaccines For Shelf Stability And Global Access

From Powder To Particles With Jet Milling

Particle Size Control Through Micronization: Challenges And Solutions

Solid Form Screening Of Active Pharmaceutical Ingredients

Capacity Update May 2024: Small Molecule APl And HPAPI Development

PBPK Modeling: Mitigating Absorption Risks In Early Drug Development

Environmental Sustainability: Wastewater Incineration Reduction

Process Re-Design For Sustainability In Small Molecule Manufacturing

How To Safely Handle Your Antibody Drug Conjugate

How To Deal With The Complexity Of Drugs In Clinical Development

How To Design An HPAPI Plant And Its Containment Systems

Environmental Sustainability: Use Case - Solvent Recovery

Local Delivery For Treatment Of Lung Cancer

Identify And Mitigate Absorption Risks With PBPK Modeling

Meeting The Challenge Of Rising API Complexity

Continuous Flow Techniques For Fine Chemical Manufacturing

Secure And Industrialize Your CGT Process Towards cGMP Manufacturing

Scale-Up Allogeneic Cell Therapies To Large Patient Populations

Improved And Rebalanced Plasmids To Ramp Up Your AAV Productivity

Path To IND: AAV Transient Transfection, Producer Cell Line Platforms

The CDMO Value Proposition For Your Autologous Cell Therapy

Scalable Suspension LVV Production Platforms

An End-To-End Industrialization Roadmap For Autologous Cell Therapy

Keys To A Successful cGMP Manufacturing Operation Delivering CGTs

De-Risk Your Path To Clinic With An AAV Suspension Platform

Preparing For FDA Pre-Approval Inspection: Quality And Regulatory Topics

Improved And Rebalanced Plasmids To Ramp Up Your AAV Productivity

Secure And Industrialize Your CGT Process Towards cGMP Manufacturing

Scalable Suspension LVV Production Platforms

De-Risk Your Path To Clinic With An AAV Suspension Platform

Path To IND: AAV Transient Transfection, Producer Cell Line Platforms

Secure And Industrialize Your CGT Process Towards cGMP Manufacturing

The CDMO Value Proposition For Your Autologous Cell Therapy

An End-To-End Industrialization Roadmap For Autologous Cell Therapy

Keys To A Successful cGMP Manufacturing Operation Delivering CGTs

Preparing For FDA Pre-Approval Inspection: Quality And Regulatory Topics

Scale-Up Allogeneic Cell Therapies To Large Patient Populations

Preparing For FDA Pre-Approval Inspection: Quality And Regulatory Topics

Secure And Industrialize Your CGT Process Towards cGMP Manufacturing

Keys To A Successful cGMP Manufacturing Operation Delivering CGTs